ESLO TAN
Main information
- Trade name:
- ESLO TAN 10 TAB
- Active ingredient:
- S-Amlodipine,LOSARTAN POT.
- Available from:
- Zuventus
- Dosage:
- 2.5,50;MG
- Pharmaceutical form:
- TAB
- Composition:
- 10
- Medicine domain:
- Humans
- Medicine type:
- Allopathic drug
Documents
- for the general public:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- for healthcare professionals:
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for healthcare professionals.
Localization
- Available in:
-
India
- Language:
- English
Other information
Status
- Source:
- Central Drugs Standard Control Organization
- Last update:
- 09-08-2016
- The information leaflet for this product is not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain it.
Request the information leaflet for the general public.
- Access to this document is only available to registered users.
Register now for full access
10-8-2018
Human medicines European public assessment report (EPAR): Exforge HCT, amlodipine besylate / valsartan / hydrochlorothiazide, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
5-7-2018
Human medicines European public assessment report (EPAR): Exforge, amlodipine / valsartan, Revision: 21, Authorised
Europe - EMA - European Medicines Agency
4-7-2018
Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine besylate / valsartan / hydrochlorothiazide, Revision: 13, Authorised
Europe - EMA - European Medicines Agency
19-6-2018
Opinion/decision on a Paediatric investigation plan (PIP): -, Candesartan (cilexetil) / amlodipine (besylate), Therapeutic area: Cardiovascular diseases
Europe - EFSA - European Food Safety Authority EFSA Journal
13-6-2018
Human medicines European public assessment report (EPAR): Copalia HCT, amlodipine / valsartan / hydrochlorothiazide, Revision: 11, Authorised
Europe - EMA - European Medicines Agency
13-6-2018
Human medicines European public assessment report (EPAR): Twynsta, telmisartan / amlodipine, Revision: 9, Authorised
Europe - EMA - European Medicines Agency
12-6-2018
Human medicines European public assessment report (EPAR): Dafiro, amlodipine / valsartan, Revision: 23, Authorised
Europe - EMA - European Medicines Agency
12-6-2018
Human medicines European public assessment report (EPAR): Copalia, amlodipine / valsartan, Revision: 21, Authorised
Europe - EMA - European Medicines Agency
28-5-2018
Human medicines European public assessment report (EPAR): Exforge HCT, amlodipine besylate / valsartan / hydrochlorothiazide, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
14-5-2018
Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine besylate / valsartan / hydrochlorothiazide, Revision: 12, Authorised
Europe - EMA - European Medicines Agency
14-5-2018
Human medicines European public assessment report (EPAR): Dafiro, amlodipine / valsartan, Revision: 22, Authorised
Europe - EMA - European Medicines Agency
7-5-2018
Human medicines European public assessment report (EPAR): Exforge, amlodipine / valsartan, Revision: 20, Authorised
Europe - EMA - European Medicines Agency
21-4-2010
Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists
On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.
Danish Medicines Agency
24-3-2010
The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of medicines in ATC groups C09C, C09D and C09X
On 8 March 2010, a number of pharmaceutical companies put generic copies of the angiotensin II antagonist losartan on the market at prices comparable to those of the cheapest ACE inhibitors.
Danish Medicines Agency
27-6-2018
Copalia HCT (Novartis Europharm Limited)
Copalia HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4082 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1159/T/67
Europe -DG Health and Food Safety
27-6-2018
Exforge (Novartis Europharm Limited)
Exforge (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4085 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/716/T/96
Europe -DG Health and Food Safety
27-6-2018
Dafiro HCT (Novartis Europharm Limited)
Dafiro HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)4084 of Wed, 27 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1160/T/68
Europe -DG Health and Food Safety
11-6-2018
Exforge HCT (Novartis Europharm Limited)
Exforge HCT (Active substance: amlodipine besylate / valsartan / hydrochlorothiazide) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3752 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1068/T/66
Europe -DG Health and Food Safety
11-6-2018
Dafiro (Novartis Europharm Limited)
Dafiro (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3753 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/776/T/99
Europe -DG Health and Food Safety
6-6-2018
Copalia (Novartis Europharm Limited)
Copalia (Active substance: amlodipine / valsartan) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3695 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/774/T/97
Europe -DG Health and Food Safety
4-6-2018
Twynsta (Boehringer Ingelheim International GmbH)
Twynsta (Active substance: telmisartan / amlodipine) - Centralised - Yearly update - Commission Decision (2018)3625 of Mon, 04 Jun 2018
Europe -DG Health and Food Safety
29-4-2016
Veterinary medicine European public assessment report (EPAR): Lodipressin, amlodipine, Revision: 0, Refused
Europe - EMA - European Medicines Agency